Send to

Choose Destination
J Diabetes Complications. 2019 Jan;33(1):1-3. doi: 10.1016/j.jdiacomp.2018.11.001. Epub 2018 Nov 8.

Targeting inflammation to reduce ASCVD in type 2 diabetes.

Author information

VA Medical Center, Mather, CA, United States of America; California Northstate University College of Medicine, Elk Grove, CA, United States of America. Electronic address:
University at Buffalo, Buffalo, NY, United States of America.


ASCVD is the leading cause of mortality in T2DM. Inflammation appears to be pivotal in the genesis of ASCVD. As T2DM is also a pro-inflammatory state, our aim was to determine the benefit of anti-inflammatory strategies on ASCVD in T2DM. PubMed searches were conducted using the keywords of T2DM, ASCVD, Inflammation and clinical trials. Our data review suggests that the Mediterranean diet, GLP1 receptor agonists and a monoclonal antibody against IL-1 reduces ASCVD events in T2DM. The former 2 therapies appear to be safe. Anti-IL-1 therapy resulted in an increase mortality from infections. We conclude that only the Mediterranean diet and GLP1 receptor agonists can be safely incorporated into mainstay therapy for patients with T2DM to reduce ASCVD. Further studies are required with respect to biologics targeting Inflammation to establish benefit to risk ratio.


Atherosclerosis; Diabetes; GLP-1 receptor agonist; Inflammation; Interleukin-1; Statin

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center